Since it has been shown that PARP1 inhibition can ameliorate numerous inflammatory conditions, including rheumatoid arthritis, asthma, atherosclerosis and allergy-, toxicity- and injury-induced inflammation, the addition of a PARP inhibitor might similarly improve TB therapy by reducing inflammation and lung damage (75, 79, 87). The gene discussed is PARP1; the disease is atherosclerosis.